🚨 #REVIEW🚨
Hong & Li explore how DNA damage response (DDR) defects shape tumour immunogenicity & influence responses to immune checkpoint blockade. They further highlight resistance mechanisms and DDR-immunotherapy combination strategies.
👇 📖
https://t.co/r8jOXF6Yvi
This is the second abstract I was waiting for the whole @AACR#AACR26#Daraxonrasib +GemNabPablitaxel in #mKRAS#PDAC in #FirstLine (GI-102 Platform)
Phase I/II trial
40 pts
ORR 58%
DCR 90%
84% free of progresion at 6 months
Ongoing Phase III 303 (Dara vs GemNab+/-Dara)
🚨🚨🚨
RASOLUTE-302 Ph3 is POSITIVE
"Daraxonrasib demonstrated a median OS of 13.2 months versus 6.7 months for chemotherapy, with a hazard ratio of 0.40 (p < 0.0001)".... WOW!
AMAZING news for patients with #PancreaticCancer
The RAS Revolution is ON!!
https://t.co/I59NNWRB1O
Neoadjuvant GOLP in Resectable High-Risk Intrahepatic Cholangiocarcinoma
@NEJM
https://t.co/qTZ3ZgVxaQ
👉EFS: 18.0 vs 8.7 mo
👉OS: NE vs 31.4
🧐Exciting, we need to explore peri-operative therapies in BTC
@myESMO@ASCO@EASLnews@ILCAnews@curecc
Single-cell integration and multi-modal profiling reveals phenotypes and spatial organization of neutrophils in colorectal cancer https://t.co/0FLusa7vuB
📣New @JHepatology paper now available in full pdf
😊OS surrogate end-points in #BiliaryMalignancies
👉PFS better than others (ORR, DCR)
📊Target HR in PFS should be around 0.6 to increase likelihood of reaching OS benefit
https://t.co/ZDcRoDPT24
@GrupoTTD@MacarullaTeresa
A study in @NatImmunol uses a model of lipopolysaccharide injection in humans to characterize the transcriptomic landscape of bone marrow and blood immune cells during the hyperinflammatory and immunosuppressed phases of systemic inflammation. https://t.co/0jldflX14T
Thrilled to share our characterization of the human tyrosine kinome.
Try out the public website: https://t.co/a5zfETTzCf
Wonderful collaboration with @CantleyLab@benturklab@LabYaffe. Many years of work led by Jared Johnson!
https://t.co/UsmA3wE78P
Pancreatic cancer immune therapy “Thus, productive cancer immune surveillance in pancreatic tumors resistant to checkpoint inhibition can be invoked by coactivation of complementary myeloid signaling pathways” Science Immunology https://t.co/Qp2NMhKsev
Thrilled to contribute to the establishment of a national research project focusing on small intestine cancer in Denmark. The creation of a biobank and the exploration of the genetics behind this rare cancer form signify a big leap forward to better stratify future patients.
At the cancer #immunotherapy special symposium at #ESMO23? Check out this cancer #vaccine trial led by session chair Inge Marie Svane in patients with #melanoma https://t.co/HNAq2WhH5M
The therapeutic potential of targeting regulated non-apoptotic cell death https://t.co/EHbj30wwjC
A new review on necroptosis, pyroptosis, parthanatos, ferroptosis, cuproptosis, lysozincrosis, disulfidptosis, and the potential for small-molecule drugs inhibiting these pathways
2) Dougan lab showed a beautiful mechanism by which cIAP1/2 antagonism activates non-canonical NF-kB signaling to induce class I-independent phagocytosis by MACROPHAGES, allowing immune recognition of tumors that ⬇️ class I or IFNG sensing👉🏽 https://t.co/K0Wn2rR9HW
RMC-6236 is a RASMULTI(ON) inhibitor from Revolution Medicines currently in clinical trials in KRAS-mutated solid cancers. RevMed has recently posted the preprint of the related preclinical compound RMC-7977:
https://t.co/SZaxGjHlBG
- RMC-7977 demonstrated potent preclinical activity in various cancer models with KRAS codon 12 mutations (KRASG12X)
- A RASMULTI(ON) inhibitor is able to bypass compensatory feedback from wild type KRAS, as well as secondary mutations in RAS alleles
- Although KRAS G12C is not included in the current RevMed phase 1, there is preclinical data here (👇🏽) showing RMC-7977 can bypass Adagrasib & Sotorasib resistance. This will become an increasingly common scenario in the clinic where patients will have seen one KRAS inhibitor & on progression will be re-challenged with a different agent.
- In conjunction with the recent paper from Piro Lito & BI (👇🏽) this is the second allele agnostic KRAS inhibitor, albeit with a distinct biochemistry.
https://t.co/rSL9zBtENa